in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Boehringer to Acquire California Biotech Firm
1:35 PM MDT | June 30, 2008 | Deepti Ramesh
Boehringer Ingelheim says it has agreed to acquire privately owned biopharmaceutical company Actimis Pharmaceuticals (San Diego) for as much as $515 million, depending on the successful development of an Actimis asthma drug. The deal is to be done in phases, depending on the progress of the asthma compound AP768, which is in phase 1 of clinical development. If AP768 successfully advances into phase III, Boehringer Ingelheim will own 100% of Actimis’ shares, Boehringer Ingelheim says. Actimis focuses on R&D of small-molecule therapeutics for severe...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee